Patents by Inventor Chun Chow

Chun Chow has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Polybasic bacterial efflux pump inhibitors and therapeutic uses thereof
    Patent number: 8178490
    Abstract: Disclosed are compounds having polybasic functionalities. The compounds inhibit bacterial efflux pump inhibitors and are used in combination with an anti-bacterial agent to treat or prevent bacterial infections. These combinations can be effective against bacterial infections that have developed resistance to anti-bacterial agents through an efflux pump mechanism.
    Type: Grant
    Filed: November 5, 2009
    Date of Patent: May 15, 2012
    Assignee: Rempex Pharmaceuticals, Inc.
    Inventors: Tomasz Glinka, Olga Rodny, Keith A. Bostian, David M. Wallace, Robert I. Higuchi, Chun Chow, Chi Ching Mak, Gavin Hirst, Brian Eastman
  • POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF
    Publication number: 20100152098
    Abstract: Disclosed are compounds having polybasic functionalities. The compounds inhibit bacterial efflux pump inhibitors and are used in combination with an anti-bacterial agent to treat or prevent bacterial infections. These combinations can be effective against bacterial infections that have developed resistance to anti-bacterial agents through an efflux pump mechanism.
    Type: Application
    Filed: November 5, 2009
    Publication date: June 17, 2010
    Applicant: Mpex Pharmaceuticals, Inc.
    Inventors: Tomasz Glinka, Olga Rodny, Keith A. Bostian, David M. Wallace, Robert I. Higuchi, Chun Chow, Chi Ching Mak, Gavin Hirst, Brian Eastman
  • Thiazole inhibitors targeting resistant kinase mutations
    Publication number: 20070161645
    Abstract: A compound is provided, having the general structure (A): wherein A is an aryl or heteroaryl group, Y is a hydrophbic linking moiety, and L is a substitutent. The compound (A) can be used for treatment of various angiogenic-associated or hematologic disorders, such as myeloproliferative disorders in patients who do not respond to kinase-inhibition therapy that comprises administering currently used medications.
    Type: Application
    Filed: October 31, 2006
    Publication date: July 12, 2007
    Applicant: TargeGen, Inc.
    Inventors: Glenn Noronha, Jianguo Cao, Binqi Zeng, Chi Mak, Andrew McPherson, Joel Renick, Ved Pathak, Chun Chow, Moorthy Palanki, Richard Soll, Daniel Lohse, John Hood, Elena Dneprovskaia
  • Six membered heteroaromatic inhibitors targeting resistant kinase mutations
    Publication number: 20070149508
    Abstract: A compound is provided, having the general structure (A): wherein A is an (un)substituted aryl or (un)substituted heteroaryl moiety, G is N, CH, or CR, R is an unsubstituted or substituted lower alkyl, Y is a hydrophobic linking moiety, and L is a substitutent as defined. The compound (A) can be used for treatment of various angiogenic and hematological-associated disorders, such as myeloproliferative disorder in patients who do not respond to kinase-inhibition therapy that comprises administering approved medications.
    Type: Application
    Filed: October 31, 2006
    Publication date: June 28, 2007
    Applicant: TargeGen, Inc.
    Inventors: Glenn Noronha, Jianguo Cao, Binqi Zeng, Chi Mak, Andrew McPherson, Joel Renick, Ved Pathak, Chun Chow, Moorthy Palanki, Richard Soll, Daniel Lohse, John Hood, Elena Dneprovskaia